rpx7009 has been researched along with Drug-Related-Side-Effects-and-Adverse-Reactions* in 1 studies
1 other study(ies) available for rpx7009 and Drug-Related-Side-Effects-and-Adverse-Reactions
| Article | Year |
|---|---|
Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.
Meropenem-vaborbactam is a fixed-dose combination product of a carbapenem and a cyclic boronic acid β-lactamase inhibitor with potent in vitro activity against Klebsiella pneumoniae carbapenemase-producing carbapenem-resistant Enterobacteriaceae (CRE). The efficacy of meropenem-vaborbactam for the treatment of complicated urinary tract infections and acute pyelonephritis was demonstrated in a Phase III trial (TANGO I). Preliminary data from TANGO II, a separate Phase III study, support the efficacy of meropenem-vaborbactam for the treatment of infections caused by CRE. Overall, meropenem-vaborbactam appears to be safe and well tolerated. It has favorable toxicity, pharmacokinetic and pharmacodynamic profiles compared with other antibiotics with activity against CRE. Meropenem-vaborbactam is an important addition to the current armamentarium of antimicrobial agents with activity against K. pneumoniae carbapenemase-producing CRE. Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Boronic Acids; Clinical Trials, Phase III as Topic; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Gram-Negative Bacterial Infections; Humans; Meropenem; Treatment Outcome; Urinary Tract Infections | 2018 |